Drugmaker admits paying kickbacks to boost transplant drug prescriptions
Veloxis Pharmaceuticals Inc., a Cary, North Carolina-based drug manufacturer, has agreed to pay more than $46 million to resolve criminal and civil allegations that it paid kickbacks to boost prescriptions and purchases of Envarsus XR, a kidney transplant immunosuppression drug, according to the Justice Department.
Veloxis Pharmaceuticals Inc. will pay over $46 million to resolve criminal and civil allegations. The company is accused of paying kickbacks to increase prescriptions and sales of its kidney transplant drug, Envarsus XR. This settlement was announced by the Justice Department.
- Veloxis Pharmaceuticals Inc. will pay over $46 million.
- The payment resolves criminal and civil allegations.
- The company allegedly paid kickbacks to boost prescriptions and purchases of Envarsus XR.
- Envarsus XR is an immunosuppression drug for kidney transplants.
- The Justice Department announced the settlement.
Write a comment